Testing a new radioactive treatment for rare neuroendocrine cancers

[225Ac]Ac-ETN029 is an experimental radioactive medication that targets cancer cells with a specific protein called DLL3. This trial is testing whether the medication is safe and whether it can slow or shrink several types of advanced neuroendocrine cancers—including small cell lung cancer, prostate cancer, and cancers of the pancreas, thyroid, and other organs. The study will enroll about 123 patients across multiple centers and will test different doses to find the safest and most effective amount.

Neuroendocrine cancers are aggressive and often difficult to treat, especially once they have spread or stopped responding to standard chemotherapy. This medication works differently than existing treatments by using radioactive particles to directly attack cancer cells that express DLL3, offering hope for patients who have run out of other options.